NeuroNEXT

In a January/February 2013 editorial, the president of the Child Neurology Society praises the formation of the NeuroNEXT Network and the possibility for it to rapidly evaluate new treatments for neurological disorders.

The NeuroNEXT Network achieved an important milestone with the publication of the primary results from the first completed NeuroNEXT study, NN101 SMA, in the December 2017 issue of Annals of Neurology. 

MediciNova announces the abstract from the NN102 SPRINT-MS study was selected as a platform presentation for late-breaking presentation at the 7th joint ECTRIMS-ACTRIMS meeting. Robert Fox will give the presentation of top line data on October 28, 2017 in Paris.

The NN103 Beat MG study Principal Investigator announces the release of two videos to raise awareness about myasthenia gravis (MG) and to provide details about the clnical trial. The first is an overview of the disease. The second, an overview of the study.

MG is a chronic autoimmune neurological disorder of neuromuscular transmission affecting approximately 75,000 individuals in the US alone. Common symptoms include a drooping eyelid, double vision, slurred speech, difficulty chewing and swallowing, weakness in the arms and legs, chronic muscle fatigue, and difficulty breathing. Despite current therapies a subset of patients continue to have symptoms or have intolerable medication side effects. The purpose of the NN103 Beat MG study is to find out the effect and safety of a new use of the drug rituximab in MG patients who are on prednisone. Please visit the NN103 Beat MG study page for further information.

Chris Coffey and Laurie Gutmann presented at the 2014 NINDS-funded Clinical Trials Methodology Course. 

View the poster presented at the 2013 Families of SMA Annual Meeting by the NN101 SMA team.